Chronic Hand Eczema: Addressing Barriers to Care Through Treatment Advancements, October 2024 (Vol. 45. Supp. 08)

Treatment with delgocitinib led to a significant decrease in the expression of inflammatory markers that were elevated in severe cases compared with mild cases at baseline.

Learn more about the in-depth topics covered in the November 2024 CHE digital supplement of Dermatology Times.

Click here to test your knowledge and read more about the treatment landscape of chronic hand eczema.

This review of the latest dermatologic studies includes discussions on the development of the Hand Eczema Impact Scale, the role of tofacitinib on Th1 and Th2 cytokines, and more.

Christopher Bunick, MD, PhD, addresses common barriers in recognizing and treating chronic hand eczema and its significant impact on quality of life.

The data was presented at the European Society of Contact Dermatitis in Dresden, Germany, this week.